Sign in
Taking people in United StatesNo phase

Tests glucose sensor use in pregnant women with type 2 diabetes

Compares a continuous glucose sensor with fingerstick checks in pregnant adults with type 2 diabetes.

Key facts

Who runs it
University of Massachusetts, Worcester
Where
Worcester, United StatesSee the site
Trial code
Registry title
Continuous Glucose Monitor Use in Pregnancy
Status
Recruiting
People taking part
180 people, planned
Started
23 May 2024
Expected to end
1 Jul 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Continuous Glucose Monitor
  • Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
Record updated
3 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with type 2 diabetes who are early in a single pregnancy. It compares a continuous glucose monitor with fingerstick blood sugar checks.

Age
18 years or older
Sex
Women only
Disease stage
Type 2 diabetes confirmed by lab tests: hemoglobin A1c 6.5% (48 mmol/mol) or higher, oral glucose tolerance test 200 mg/dL (11.1 mmol/L) or higher, or fasting plasma glucose 126 mg/dL (7 mmol/L) or higher. Pregnant with one baby, 14 weeks or less at the first obstetric visit.

Main reasons for not taking part

  • Type 1 diabetes
  • Gestational diabetes
  • Pregnant with more than one baby
  • Plans prenatal care or delivery outside UMMHC
  • Cannot give informed consent

This trial only enrols pregnant participants. The registry sentence this rests on: 2) singleton gestation less than or equal to 14 weeks at initial obstetric visit

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • 1) age greater than or equal to 18 years old
  • 2) singleton gestation less than or equal to 14 weeks at initial obstetric visit
  • 3) established diagnosis of T2DM by laboratory criteria including hemoglobin A1c ≥6.5%, oral glucose tolerance test ≥200 mg/dL, or fasting plasma glucose ≥126 mg/dL
  • 4) receiving prenatal care at UMASS Memorial Health Care (UMMHC) and plans to deliver at UMMHC
  • 5) able and willing to provide informed consent

Who cannot take part

  • 1) known diagnosis of type 1 diabetes or gestational diabetes
  • 2) plan to receive prenatal care or delivery outside of UMMHC
  • 3) inability to provide informed consent
  • 4) multifetal gestation

Where in United States

  • University of Massachusetts Memorial Medical CenterWorcester, United StatesContact: Gianna L Wilkie, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to perform a randomized controlled trial among 180 pregnant women with type 2 diabetes mellitus (T2DM) comparing continuous glucose monitor (CGM) use to the standard of care of multiple daily fingerstick glucose monitoring and its impact on large for gestational age infants, maternal glycemic control, patient satisfaction, and additional adverse perinatal outcomes.

The 2 groups in the trial

  • Continuous Glucose Monitoring (CGM)Treatment being tested

    Patients will be randomized to application of a continuous glucose monitor (CGM). They will apply the device in the clinical setting and be instructed how to download their information onto their smartphones or using the CGM device reader. They will use the CGM for the duration of the pregnancy until delivery.

    Treatment: Continuous Glucose Monitor

  • Fingerstick Glucose MonitoringExisting treatment, for comparison

    Patients will be randomized to checking their blood glucose with fingerstick monitors at time of fasting in the AM, and 2 hours after each meal. This is the standard of care for patients in the pregnancy diabetes clinic.

    Treatment: Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Continuous Glucose Monitor Use and Perinatal Outcomes Among Pregnant Women With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Plain-language title
Tests glucose sensor use in pregnant women with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 August 2026